Search by Abstract Number Results

Abstract Number: 2729 • 2019 ACR/ARP Annual Meeting
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar¹, Désirée van der Heijde ², Lianne Gensler ³, Tae-Hwan Kim ⁴, Walter P. Maksymowych ⁵, Mikkel Østergaard ⁶, Denis Poddubnyy ⁷, Helena Marzo-Ortega ⁸, Louis Bessette ⁹, Tetsuya Tomita ¹⁰, Gaia Gallo ¹¹, David Adams ¹¹, Ann Leung ¹², Fangyi Zhao ¹¹, Maja Hojnik ¹¹, Hilde Carlier ¹³ and Joachim Sieper ¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³University San Francisco California, San Francisco, CA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ⁹Laval University, Quebec City, QC, Canada, ¹⁰Osaka University Graduate School of Medicine, Osaka, Japan, ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Syneos Health, Raleigh, NC, ¹³Eli Lilly and Company, Indianapolis, ¹⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and…
Abstract Number: 2729 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Cerebrovascular Accident Among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-Analysis of Cohort Studies
Patompong Ungprasert¹, Karn Wijarnpreecha² and Wisit Cheungpasitporn³, ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Internal medicine, Bassett medical center, cooperstown, NY, ³Medicine, University of Mississippi Medical center, Jackson, MS
Increased Risk of Cerebrovascular Accident among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-analysis of Cohort StudiesAbstractBackground/Purpose: An increased risk of cardiovascular…
Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Hasan Tuzun¹, Gul Guzelant², Ozkan Demirhan³, Buge Oz⁴, Izzet Fresko², Vedat Hamuryudan², Hasan Yazici² and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…
Abstract Number: 2729 • 2016 ACR/ARHP Annual Meeting
Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States
Alice Gottlieb¹, Jorge Gratacos-Masmitja², April Armstrong³, Jo Lambert⁴, Astrid van Tubergen⁵, Ara Dikranian⁶, Birol Emir⁷, Eustratios Bananis⁸, Tim Smith⁷, Laraine Aikman⁹ and Linda Chen⁷, ¹Tufts University School of Medicine, Boston, MA, ²Servicio de Reumatología, Corporació Sanitoria Parc Taulíde Sabadell, Barcelona, Spain, ³Department of Dermatology, University of Southern California, Los Angeles, CA, ⁴Department of Dermatology, Ghent University Hospital, Ghent, Belgium, ⁵Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶San Diego Arthritis Clinic, San Diego, CA, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Ltd, Walton Oaks, United Kingdom
Background/Purpose: This non-interventional, cross-sectional descriptive exploratory analysis aimed to characterize patients (pts) with PsA in the 2015 National Health and Wellness Survey (NHWS) and determine…
Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 2729 • 2014 ACR/ARHP Annual Meeting
To Live or Let Die… the Battle Between PD-1 and OX40 on SLE T Cells
Julie Kristine Laustsen¹, Stinne Greisen², Bent Deleuran³ and Tue Kruse Rasmussen⁴, ¹Aarhus University, Aarhus C, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Dept of Biomedicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Programmed cell death 1 (PD-1) is a co-inhibitory receptor, which inhibits T cell proliferation and survival by inhibiting IL-2 signalling. By this PD-1 has…
Abstract Number: 2729 • 2013 ACR/ARHP Annual Meeting
Identification Of Osteoarthritis Patients With Chronic Inflammation Driven Disease Progression
Anne Sofie Siebuhr¹, Kristian Kjaer Petersen², Lars Arendt-Nielsen³, Line Egsgaard², Thomas Navndrup Eskehave⁴, Ole Simonsen⁵, Claus Christiansen^4,6, Hans Christian Hoeck⁴, Morten Asser Karsdal⁷ and Anne C. Bay-Jensen⁸, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ³Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁴Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁵Frederikshavn Hospital, Frederikshavn, Denmark, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁸Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: In osteoarthritis (OA) it is evident that a subset of patients experiences chronic tissue inflammation and may benefit from anti-inflammatory treatment. The systemic inflammation…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].